Comerica Securities’s Vaxcyte PCVX Stock Holding History

Comerica Securities’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-336	Closed	-$16.1K	–	1135
2022 Q4	$16.1K	Buy	+336	New	+$13.2K	﹤0.01%	947

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Comerica Securities's PCVX Position: Q1 2023 in Review

Comerica Securities sold out of Vaxcyte (PCVX) in Q1 2023, closing a stake of 336 shares — an estimated $16.1K sold.

Comerica Securities first reported a position in PCVX in Q4 2022 and held it in 1 quarter. The position peaked at $16.1K in Q4 2022. 187 funds tracked by Wall St. Rank hold PCVX as of Q1 2023.

Comerica Securities reported no remaining Vaxcyte position as of Q1 2023 after selling out during the quarter.
Comerica Securities sold 336 Vaxcyte shares in Q1 2023, an estimated $16.1K.
Comerica Securities first reported a position in Vaxcyte in Q4 2022 and held it in 1 quarter.
Comerica Securities's Vaxcyte position peaked at $16.1K in Q4 2022.
187 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.